Yuyu Pharma Acquires 2 Billion KRW Worth of Treasury Shares as Part of Shareholder-Friendly Policy

Yuyu Pharmaceutical Headquarters. Photo by Yuyu Pharmaceutical

Yuyu Pharma is undertaking a treasury stock acquisition worth 2 billion KRW as part of its shareholder-friendly policies to enhance shareholder value.

This treasury stock acquisition will be conducted through on-market purchases on the KOSPI market, with a planned acquisition of 471,142 common shares and a total acquisition amount of 2 billion KRW. Yuyu Pharma currently holds approximately 850,000 common treasury shares, and upon completion of this acquisition, it will hold treasury shares equivalent to 7.8% of the total issued common shares.

Since 1994, Yuyu Pharma has paid cash dividends for 29 consecutive years, and this year, it paid a total dividend amount of approximately 2 billion KRW, with a cash dividend of 100 KRW per common share and 120 KRW per preferred share. Additionally, the company has consistently implemented shareholder-friendly policies annually, including a 1 billion KRW treasury stock purchase in 2020, a 100% stock dividend in 2021, a 2 billion KRW treasury stock purchase in 2022, and the cancellation of 200,000 treasury shares in 2023.

Park Noyong, CEO of Yuyu Pharma, stated, "We will continue to strive to enhance the value for our shareholders, including individual investors who trust and invest in Yuyu Pharma’s corporate value and growth potential through shareholder-friendly policies."

Meanwhile, Yuyu Pharma recorded consolidated sales of 133.1 billion KRW, operating profit of 11.6 billion KRW, and net profit of 10.2 billion KRW last year, achieving a turnaround in performance and increased profitability. As a new growth engine, the company has targeted the pet industry and invested in U.S. startups developing animal pharmaceuticals.